Sab biotherapeutics announces first publication of promising nonclinical data for sab-183 against pneumonic plague in the journal antibodies

In study conducted for u.s. army medical research institute, sab-183 demonstrated strong immune protection and response against yersinia pestis infection, which causes plague

SABS Ratings Summary

SABS Quant Ranking